D. Boral Capital initiated coverage of Turn Therapeutics with a rating of Buy and set a new price target of $8.00

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

424B3 - Turn Therapeutics Inc. (0002023016) (Filer)

424B3 - Turn Therapeutics Inc. (0002023016) (Filer)

10-Q - Turn Therapeutics Inc. (0002023016) (Filer)

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

424B5 - Turn Therapeutics Inc. (0002023016) (Filer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

3 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track to complete both interim analysis and topline data in first half of 2026 Appointment of Martin Dewhurst, a 30+ years McKinsey & Company M&A veteran, strengthens Company board of directors Expansion of intranasal vaccine pipeline to include intranasal Influenza candidate that may stimulate systemic immunity via targeted intranasal exposure without adjuvants or potentially harmful additives Progress on commercial partnerships with expected revenue generation in 2026 in advanced wound care market Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and

LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, advanced wound care, and infectious diseases, announced today the appointment of Mr. Martin Dewhurst to its Board of Directors. Mr. Dewhurst brings more than 30 years of global leadership experience in life sciences, with a particular focus on mergers and acquisitions. "Martin's appointment comes at a pivotal moment for Turn Therapeutics as we advance a disciplined, M&A-focused strategy to expand our pipeline and accelerate long-term value creation," said Bradley Burnam, Chief Executive Office

Successfully began trading on NASDAQ under ticker TTRX on October 8, 2025 Strengthened its Board of Directors with the appointments of Arthur Golden and Dr. Kent Kester Entered into a global supply, development, and license agreement with leading medical-surgical product manufacturer and distributor Medline LOS ANGELES, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today reported financial results for the third quarter ended September 30, 2025, and provided corporate updates. "Our first weeks as a public company have been extremely productive, an

LOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced that Chief Executive Officer, Brad Burnam, spoke with Dr. Robert Redfield, M.D., former Director of the Centers for Disease Control and Prevention (CDC) about healthcare communication and ways to restore public trust in science. The interview, titled "Redfield's Warning: Former CDC Director on COVID's Biggest Casualty-Trust in Science," can be accessed on all major podcast platforms, via YouTube here, or on the Turn Therapeutics IR Website here. "It was a pleasure speaking with

LOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced it has been named as one of the "Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment" by Patient Care Online Magazine. "We are honored to have our GX-03 technology be recognized as a top innovation by this widely read online magazine and this surprise designation further validates our goal of bringing best-in-class eczema products to patients in need," said Bradley Burnam, Founder and Chief Executive Officer of Turn Therapeutics. "IL-36 is implicated in the inflammatory

LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced the appointment of Andrew Scott as Vice President of Corporate Communications. In this new role, Mr. Scott will oversee investor relations, capital markets strategy, and corporate communications, while supporting the Company's licensing and partnership initiatives. "We are thrilled to welcome Andrew to this newly created senior executive role. His addition comes as Turn Therapeutics enters a new phase of growth following its public listing and strengthened balance sheet. Andrew

WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (NASDAQ:TTRX) ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, today announced it has entered into a global supply, development, and license agreement with Medline, the largest provider of medical-surgical products and supply chain solutions serving all points of care. The agreement establishes a long-term collaboration to develop, manufacture, and commercialize products leveraging Turn's proprietary PermaFusion® delivery platform. Turn Therapeutics CEO Bradley Burnam commented, "Partnering with Medline represents a tr

WESTLAKE VILLAGE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (NASDAQ:TTRX) ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, provides a shareholder update outlining continued progress in the advancement of its clinical programs while highlighting the flexibility of its financing strategy following its dilution-sparing direct listing. Capital Strategy and AlignmentTurn chose a direct listing structure to prioritize flexibility and long-term shareholder alignment. By bypassing traditional crossover rounds and IPO share issuance, early shareholders maintained their ownership position

LOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (NASDAQ:TTRX) today announced the launch of a broad communications initiative, featuring a recurring webinar series for shareholders and a forthcoming Founder Blog authored by patient-turned-founder and CEO, Bradley Burnam. "It is an uncommon step to maintain constant engagement with shareholders, partners, and the broader healthcare community," said Bradley Burnam, Founder and CEO of Turn Therapeutics. "But this company was built by a deeply engaged community, and we intend to continue that conversation as we grow." The Founder Blog will publicly share ongoing company updates, research insights, and perspectives on Turn's

WESTLAKE VILLAGE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces the appointment of Kent E. Kester, MD, FACP, FIDSA, FASTMH to its Board of Directors. Dr. Kester is a globally recognized infectious disease physician and R&D leader with extensive experience spanning clinical development, translational medicine, vaccine and anti-infective innovation, and public-private collaboration. A retired U.S. Army Colonel, he has held senior leadership roles across industry and academia, including as Commander of the Walter Reed Army Inst

Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track to complete both interim analysis and topline data in first half of 2026 Appointment of Martin Dewhurst, a 30+ years McKinsey & Company M&A veteran, strengthens Company board of directors Expansion of intranasal vaccine pipeline to include intranasal Influenza candidate that may stimulate systemic immunity via targeted intranasal exposure without adjuvants or potentially harmful additives Progress on commercial partnerships with expected revenue generation in 2026 in advanced wound care market Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and

LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, advanced wound care, and infectious diseases, announced today the appointment of Mr. Martin Dewhurst to its Board of Directors. Mr. Dewhurst brings more than 30 years of global leadership experience in life sciences, with a particular focus on mergers and acquisitions. "Martin's appointment comes at a pivotal moment for Turn Therapeutics as we advance a disciplined, M&A-focused strategy to expand our pipeline and accelerate long-term value creation," said Bradley Burnam, Chief Executive Office

LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced the appointment of Andrew Scott as Vice President of Corporate Communications. In this new role, Mr. Scott will oversee investor relations, capital markets strategy, and corporate communications, while supporting the Company's licensing and partnership initiatives. "We are thrilled to welcome Andrew to this newly created senior executive role. His addition comes as Turn Therapeutics enters a new phase of growth following its public listing and strengthened balance sheet. Andrew

WESTLAKE VILLAGE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces the appointment of Kent E. Kester, MD, FACP, FIDSA, FASTMH to its Board of Directors. Dr. Kester is a globally recognized infectious disease physician and R&D leader with extensive experience spanning clinical development, translational medicine, vaccine and anti-infective innovation, and public-private collaboration. A retired U.S. Army Colonel, he has held senior leadership roles across industry and academia, including as Commander of the Walter Reed Army Inst

WESTLAKE VILLAGE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces the appointment of Arthur Golden, a senior corporate board advisor with extensive experience in M&A transactions, shareholder relations, compliance, and governance, to its Board of Directors. He has decades of experience as a corporate director, most recently as a Director of Emerson Electric where he served for 24 years and chaired the Corporate Governance and Finance Committees and was a member of the Executive Committee. Mr. Golden brings decades of experienc